Close Menu

NEW YORK (GenomeWeb) – Biodesix announced today that it has chosen Progenetics to market and distribute its liquid biopsy tests in Israel.

Under the terms of the agreement, Tel Aviv-based Progenetics will market and distribute Biodesix's GeneStrat and VeriStrat tests, which are available for clinical use in patients with non-small cell lung cancer (NSCLS).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.